

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock code: 00241)

DELAY IN DESPATCH OF CIRCULAR

**(1) DISCLOSEABLE AND CONNECTED TRANSACTION AND
(2) CONTINUING CONNECTED TRANSACTIONS**

We refer to the announcement of Alibaba Health Information Technology Limited (the “**Company**”) dated February 6, 2020 (the “**Announcement**”) in relation to, among other things, the Share Purchase Agreement entered into between the Company and the Vendor, pursuant to which the Company will acquire a 100% equity interest in the Target Company. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, a circular (the “**Circular**”) containing, among other things, further details of the Share Purchase Agreement, further details of the Framework Technical Services Agreement, the advice and recommendations of the Independent Board Committee, the advice and recommendations of the Independent Financial Adviser, together with a notice of the SGM is expected to be despatched to the Shareholders on or before February 27, 2020. As more time is required to finalize certain information to be included in the Circular, the Company expects that the despatch date of the Circular will be delayed to a date on or around March 12, 2020.

By Order of the Board

ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

SHEN Difan

Chief Executive Officer and Executive Director

Hong Kong, February 27, 2020

As at the date of this announcement, the Board comprises eight Directors, of whom (i) two are executive Directors, namely, Mr. SHEN Difan and Mr. WANG Qiang; (ii) three are non-executive Directors, namely Mr. WU Yongming, Mr. WANG Lei and Mr. XU Hong; and (iii) three are independent non-executive Directors, namely Mr. LUO Tong, Mr. WONG King On, Samuel and Ms. HUANG Yi Fei (Vanessa).